

# Review of: "Challenges in identifying biomarkers for Smooth muscle tumors of uncertain malignant potential (STUMP)"

Yasunaga Masafumi<sup>1</sup>

<sup>1</sup> Kyushu University

**Potential competing interests:** No potential competing interests to declare.

Thank you for inviting me to review for this manuscript.

I'm agree with your opinion that it is necessary to predict a clinical course of uterine mesenchymal tumors by not only pathological findings but also key biomarkers that has been found by a next-generation sequencer. I speculate that a role of pathological findings of uterine mesenchymal tumors is being limited. Especially mitotic count between pathologists is not reproducible (Silverberg SG. Hum Pathol 1976; 7(4): 451-4.)

Page 3, line 4 - 6. It is preferable to add a reference for this sentence (Similar sentence is found in a chapter of mitotically active leiomyoma in Blaustein's pathology of the female genital tract) because a uterine mesenchymal tumor with a mitotic rate of > 15/10 HPF in the absence of nuclear atypia and tumor coagulative necrosis is classified as STUMP in recent WHO classification of tumors, 5<sup>th</sup> ed.